-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2664 Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study

Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Poster III
Hematology Disease Topics & Pathways:
Diseases, Pregnancy, Immune Disorders, Study Population, Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM

Stephanie Guillet1*, Valentine Loustau2*, Anissa Zarour3*, Emmanuelle Boutin, MD4*, Thibault Comont5*, Nathalie Costedoat-Chalumeau, MD, PhD6*, Brigitte Pan-Petesch, MD7*, Delphine Gobert, M.D8*, Stephane Cheze, MD9*, Odile Souchaud-Debouverie10*, Jean-Francois Viallard11*, Anne-Sophie Morin12*, Gaetan Sauvetre13*, Manuel Cliquennois, MD, MSc14*, Bruno Royer, MD15*, Corinne Haioun, MD PhD16, Agathe Masseau17*, Louis Terriou18*, Claire Fieschi, MD, PhD19*, Matthieu Mahevas20*, Marc Michel21* and Bertrand Godeau21*

1Department of Internal Medecine, Henri Mondor University Hospital, Creteil, FRA
2Department of Internal Medecine, Henri Mondor University Hospital, Creteil, France
3Henri Mondor University Hospital, Creteil, France
4Department of Public Health and Biostatistics, Henri Mondor Hospital, Créteil, France
5Service de médecine interne, IUCT Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
6Department of Internal Medecine, Cochin University Hospital, Paris, FRA
7Haemophilia Treatment Centre, CHRU Brest, Brest, France
8Internal Medicine, Saint Antoine Hospital, Paris, France
9Service d'Hématologie Clinique, CHU Côte de Nacre, Caen, France
10Department of Internal Medecine, Miletrie University Hospital, Poitiers, France
11Haut-Leveque Hospital, Pessac, FRA
12Department of Internal Medicine, Bondy Hospital, Bondy, FRA
13Department of Internal Medecine, Charles-Nicolle University Hospital, Rouen, France
14Hôpital Saint Vincent De Paul, Lille Cedex, FRA
15Department of Immuno hematology, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Paris, France
16Clinical Hematology, Henri Mondor University Hospital, UPEC, Creteil, France
17Department of Internal Medecine, Hotel Dieu Hospital, Nantes, France
18Hôpital Claude Huriez, Lille, France
19Service d’Immunologie clinique, Hôpital Saint-Louis, AP-HP, Paris, France
20Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, 94000 Créteil, Creteil, France
21Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, 94000 Créteil, Créteil, France

Background: Adult immune thrombocytopenia (ITP) is a rare autoimmune disease that can affect women of childbearing age. The effect of pregnancy on women with a pregestational diagnosis of ITP is still unclear and has never been prospectively studied. Objective: Investigate the effect of pregnancy on the course of ITP. Methods: We conducted a nationwide prospective multicenter observational case-control study (ClinicalTrials.gov NCT02892630). Thirty-three centers from the French ITP reference center network participated in the study. Over a two years period, we enrolled 131 pregnant women with a pregestational diagnosis of ITP and 131 non pregnant women of childbearing age with ITP who served as controls. Matching criteria included: history of splenectomy, disease status (defined as non-responder, responder or complete responder depending on platelet count and the need of treatment modification in the last 2 months) and ITP duration (i.e; persistent (<1 year) or chronic). Cases and controls were followed up for 15 months and platelets counts, hemorrhagic complications and treatment initiation or intensification for ITP were recorded. We defined ITP worsening by a combined score including the occurrence of bleeding and/or occurrence of severe thrombocytopenia (i.e. < 30 G/L) and/or changes in ITP disease status. Results: ITP worsening was significantly increased in pregnant women with ITP when compared to matched controls, affecting respectively 52.7% versus 38.2% (p= 0.05) of patients (figure 1). It occurred mainly during the second and third trimesters. However, the frequency of severe thrombocytopenia (28.2% vs 25.2%, p= 0.69) and incidence of bleeding (22.9% vs 15.3%, p= 0.15) were similar in both groups, even when considering severe bleeding only (Khellaf’s bleeding score >7) (16% vs 9.2%, p= 0.11).In contrast, initiation and intensification of therapy were significantly increased in pregnant women compared to matched controls, respectively 32.1% versus 20.6% (p = 0.01) of patients. Importantly, this increased need for therapy did not lead to an increase in maternal and obstetrical complications. In particular, we found no increase of complications that could have been exacerbated by corticosteroid and intravenous immunoglobulins use such as gestational diabetes or high blood pressure. Also compared to pre-gestational period, at 6 months post-partum, only 16.8% of pregnant women showed disease worsening. This frequency was comparable in the control group after 15 months follow-up (16.8%, p = 0.57). Conclusion: The current guidelines on therapy for pregnant women with pregestational ITP are mostly based on expert opinions and retrospective studies that mainly recommend treatment for pregnant women with a platelet count < 30 x 109/L. This prospective observational study investigating ITP progression during pregnancy shows that women with ITP were more intensively treated during pregnancy compared with matched controls. Paradoxically, this does not coincide with an increased of clinical or biological worsening in pregnant womenwhich raises questions of the relevance of this therapeutic conduct although we cannot exclude that these therapies may have prevented disease progression during pregnancy. Finally in late post-partum period, disease worsening was low and seems to be link to the natural course of the disease.

Disclosures: Haioun: Celgene: Honoraria; Janssen: Honoraria; Gilead: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Roche: Honoraria; Servier: Honoraria; Amgen: Honoraria; Miltenyi: Honoraria. Mahevas: GSK: Research Funding. Michel: Rigel: Consultancy; Alexion Pharmaceuticals: Consultancy; Bioverativ: Consultancy. Godeau: Novartis: Honoraria; LFB: Honoraria; Amgen: Honoraria; Amgen: Research Funding.

*signifies non-member of ASH